Klotho Neurosciences (KLTO) CEO granted 2.5M new shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Klotho Neurosciences, Inc. reported that Chief Executive Officer Joseph Sinkule acquired 2,500,000 shares of common stock on March 4, 2026 through a grant under the company’s Equity Incentive Plan. The shares were reported at a price of $0.00 per share.
Following this grant, Sinkule’s directly held common stock increased to 6,346,700 shares. This transaction reflects an equity award rather than an open-market purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
SINKULE JOSEPH
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 2,500,000 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 6,346,700 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Klotho Neurosciences (KLTO) report for Joseph Sinkule?
Klotho Neurosciences reported that CEO Joseph Sinkule received a grant of 2,500,000 shares of common stock. The award was made under the company’s Equity Incentive Plan and reflects an equity grant, not an open-market stock purchase or sale.
What transaction code was used in the Klotho Neurosciences (KLTO) Form 4 filing?
The transaction was reported with code “A,” which indicates a grant, award, or other acquisition of securities. This aligns with the footnote stating the CEO received the shares as a grant under the Equity Incentive Plan.